InspireMD has issued a voluntary recall of its CGuard Prime 135cm carotid stent delivery system in the US, following consultation with the US FDA.

TaeWoong Medical has secured the US FDA clearance to commercialise the Niti-S Spaxus Stent, expanding its range of EUS-guided therapeutic solutions.

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.

The funds will advance Axoft’s existing clinical trial programmes and progress US regulatory activities for its implantable brain-computer interface.

MintNeuro has signed a partnership with Motif Neurotech to advance the development of miniature BCI therapy for mental health conditions.

The FDA has awarded a breakthrough device designation for Capitan Orthopedics' SupraSpacer implant for patients with irreparable rotator cuff tears.

Tandem has received FDA approval for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type 1 diabetes mellitus.

According to GlobalData analyst Dr Andrew S Thompson, the deal signals Thermo Fisher’s move away from the IVD space.

Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.

Neuromodulation is an adjunct to medication for Parkinson’s symptom management, with growing interest in whether it could one day contribute to disease-modifying therapies.

Dexcom is maintaining its prior FY26 outlook in view of the current geopolitical realities such as higher oil prices due to Iran’s closure of the Strait of Hormuz in response to the US-Israel’s war ...

BrioHealth Solutions has secured conditional FDA approval to begin a clinical trial of its BrioVAD system in children diagnosed with advanced heart failure.